Log in or Sign up for Free to view tailored content for your specialty!
Inflammatory Bowel Disease News
‘Unexpectedly high’ placebo response derails darvadstrocel for Crohn’s perianal fistulas
WASHINGTON — Darvadstrocel demonstrated “no statistically significant or clinically meaningful” benefit vs. placebo for complex perianal fistulas and Crohn’s disease, according to ADMIRE-CD II trial data presented at Digestive Disease Week.
TRIUMPH: 58% of acute severe UC patients responded ‘within 2 days’ of starting Xeljanz
WASHINGTON — Nearly 60% of patients with acute severe ulcerative colitis responded to Xeljanz 10 mg twice daily by day 7, with one-third of patients in steroid-free remission by 6 months, according to interim analysis data presented here.
Log in or Sign up for Free to view tailored content for your specialty!
Simlandi launches in U.S. as third interchangeable Humira biosimilar
Simlandi injection, an interchangeable biosimilar to Humira, is now available in the U.S. for the treatment of psoriatic arthritis, plaque psoriasis and other conditions, Teva Pharmaceuticals and Alvotech announced in a press release.
SEQUENCE: Skyrizi outperforms for Crohn’s remission; Stelara ‘still remains on the table’
WASHINGTON — Although a greater number of patients with Crohn’s disease who failed anti-TNF therapy achieved biologic remission with Skyrizi vs. Stelara, choosing between the two therapies “still remains on the table,” a researcher noted.
Statin use linked to ‘sharp 86% risk reduction’ for primary sclerosing cholangitis in IBD
WASHINGTON — Statin use was associated with up to a 90% risk reduction for new-onset primary sclerosing cholangitis among patients with inflammatory bowel disease, according to data presented at Digestive Disease Week.
‘Promising’ low-calorie, plant-based diet may improve inflammation, therapy response in UC
WASHINGTON — “Even at short intervals,” an intermittent low-calorie, plant-based diet may improve inflammation and response to medical therapy among patients with moderately to severely active ulcerative colitis, according to a presenter.
Q&A: ‘Future is bright’ for use of microbiota therapeutics in patients with IBD
In a Healio exclusive, Ari Grinspan, MD, predicted that while microbiota therapeutics are currently “not ready for prime time,” they will eventually become part of the treatment strategy for patients with inflammatory bowel disease.
Novel gene variants may predict risk for co-occurring Parkinson’s disease, IBD
Novel forms of a rare genetic variant may contribute to the risk for co-occurring Parkinson’s disease and inflammatory bowel disease, according to research presented in Genome Medicine.
Low anti-TNF concentrations at week 14 linked to long-term loss of response in Crohn’s
Approximately two-thirds of patients with Crohn’s disease who initially responded to anti-tumor necrosis factor therapy lost response by 3 years, with researchers suggesting that higher drug concentrations at induction may improve outcomes.
Anti-TNF use linked to risk for progressive kidney function decline in patients with IBD
Tumor necrosis factor inhibitor use was independently associated with a greater risk for progressive kidney function decline but not risk for all-cause mortality among patients with new-onset inflammatory bowel disease, according to data.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read